Celcuity Inc.

Healthcare · Biotechnology · United States

Last price 69.3 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.39B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic...